Merck, Inc.
🇺🇸United States
A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)
- First Posted Date
- 2013-01-17
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT01770223
A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT01767688
A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 223
- Registration Number
- NCT01760447
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 307
- Registration Number
- NCT01760460
A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Matching placebo to glimepiride
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 402
- Registration Number
- NCT01755156
A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 58
- Registration Number
- NCT01756079
An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)
Phase 2
Terminated
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2012-12-03
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2211
- Registration Number
- NCT01739348
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Phase 2
Completed
- Conditions
- AnemiaMyelodysplastic SyndromesMyelodysplastic Syndromes (MDS)Chronic Myelomonocytic LeukemiaLow to Intermediate-1 MDSChronic Myelomonocytic Leukemia (CMML)
- Interventions
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 74
- Registration Number
- NCT01736683
- Locations
- 🇫🇷
Institute Paoli-Calmettes Service Haematology, Bp 156,, France
🇫🇷CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang, Lille, France
🇫🇷CHRU Nantes, Nantes, France
A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT01737684
A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)
Phase 3
Completed
- Conditions
- Pneumococcal Disease
- Interventions
- Biological: Pneumovax™ 23
- First Posted Date
- 2012-11-27
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 102
- Registration Number
- NCT01734239